Lipid nanoparticle siRNA treatment of Ebola-virus-Makona-infected nonhuman primates. - Wikidata - wikimedia - TriplyDB

Lipid nanoparticle siRNA treatment of Ebola-virus-Makona-infected nonhuman primates.

Lipid nanoparticle siRNA treatment of Ebola-virus-Makona-infected nonhuman primates.

http://www.wikidata.org/entity/Q34473079

about

The Role of microRNAs in the Pathogenesis of Herpesvirus Infection Addressing Therapeutic Options for Ebola Virus Infection in Current and Future Outbreaks Clomiphene and Its Isomers Block Ebola Virus Particle Entry and Infection with Similar Potency: Potential Therapeutic Implications Rescue of non-human primates from advanced Sudan ebolavirus infection with lipid encapsulated siRNA Experimental Treatment of Ebola Virus Disease with TKM-130803: A Single-Arm Phase 2 Clinical Trial Offering patients more: how the West Africa Ebola outbreak can shape innovation in therapeutic research for emerging and epidemic infections Insights from clinical research completed during the west Africa Ebola virus disease epidemic.Ebola Virus Infection: Review of the Pharmacokinetic and Pharmacodynamic Properties of Drugs Considered for Testing in Human Efficacy Trials.Manipulation of Viral MicroRNAs as a Potential Antiviral Strategy for the Treatment of Cytomegalovirus Infection.Therapeutic efficacy of the small molecule GS-5734 against Ebola virus in rhesus monkeys.Molecular Diagnostic Field Test for Point-of-Care Detection of Ebola Virus Directly From Blood.Synthesis and structure-activity relationships of novel cationic lipids with anti-inflammatory and antimicrobial activities.Inhibition of Hepatitis C Virus in Mice by a Small Interfering RNA Targeting a Highly Conserved Sequence in Viral IRES Pseudoknot.Large-Scale Screening and Identification of Novel Ebola Virus and Marburg Virus Entry Inhibitors Considerations in the Use of Nonhuman Primate Models of Ebola Virus and Marburg Virus Infection.The Role of a National Biocontainment Laboratory in Emergencies.Engineered Mammalian RNAi Can Elicit Antiviral Protection that Negates the Requirement for the Interferon Response.Ebola Virus Infection: Overview and Update on Prevention and Treatment.Ebola Virus Infections in Nonhuman Primates Are Temporally Influenced by Glycoprotein Poly-U Editing Site Populations in the Exposure Material.A general strategy to inhibiting viral -1 frameshifting based on upstream attenuation duplex formation.Cross-Reactive and Potent Neutralizing Antibody Responses in Human Survivors of Natural Ebolavirus Infection.A web-based resource for designing therapeutics against Ebola Virus Oral and Conjunctival Exposure of Nonhuman Primates to Low Doses of Ebola Makona Virus Short Interfering RNA Inhibits Rift Valley Fever Virus Replication and Degradation of Protein Kinase R in Human Cells.Targeted depletion of PIK3R2 induces regression of lung squamous cell carcinoma Development of experimental and early investigational drugs for the treatment of Ebola virus infections.Nucleic acid-based drugs against emerging zoonotic viruses.Infection with the Makona variant results in a delayed and distinct host immune response compared to previous Ebola virus variants.Clinical Evaluation of Ebola Virus Disease Therapeutics.Human cytomegalovirus encoded microRNAs: hitting targets.High-Yield Synthesis of Monomeric LMWP(CPP)-siRNA Covalent Conjugate for Effective Cytosolic Delivery of siRNA.Current views on inducing synthetic lethal RNAi responses in the treatment of cancer.Cationic switchable lipids: pH-triggered molecular switch for siRNA delivery.Hepatitis A virus-encoded miRNAs attenuate the accumulation of viral genomic RNAs in infected cells.Efficient Transfection of siRNA by Peptide Dendrimer-Lipid Conjugates.Effect of charge ratio on lipoplex-mediated gene delivery and liver toxicity.Polymers in the Delivery of siRNA for the Treatment of Virus Infections.Ebola Virus Shedding and Transmission: Review of Current Evidence.Trial design for evaluating novel treatments during an outbreak of an infectious disease.Analytical Validation of the ReEBOV Antigen Rapid Test for Point-of-Care Diagnosis of Ebola Virus Infection.

P2860

Q26748350-908A6A3D-DCE2-4D6B-AD79-0C1E838179E0 Q26801423-5E217DF8-28D9-4BA5-9A8D-031A69ACD654 Q28387522-AA2CBAB7-96F8-4DE2-917A-9F6220309A8F Q28396399-625053EC-3772-4867-AC91-63E337AD8BA4 Q28551448-A2A4877D-3941-4FDE-A660-59060419F1AA Q29994672-AC946E13-928C-40B0-8A57-169BB6A9F0A1 Q30234590-17C75564-50F8-4629-A0A7-ED026412700E Q30251949-91767C44-60AD-4782-A0E2-6171B3A9C679 Q33753996-04623643-94B7-434C-AC40-99D60895269B Q34516555-E0F77DA7-43C5-4A69-8267-1209654A3320 Q34540551-DEAE1EA8-8437-49CB-BA6C-155D86951E01 Q35695892-6A56B3EE-B199-4987-B8C4-1C1B0B89856E Q35890093-06D7D266-C87B-45CB-93CA-3F667B75DCB2 Q36012840-652D29F8-4221-4E90-8A49-DB8E3A0482D2 Q36043284-E8C338A4-2169-46A5-9247-6984BA1F973D Q36092115-E4E1D301-1153-497D-9BFF-DEAB9AE72ACB Q36304385-9867B1A6-4F93-4C70-AAE2-F356F934F57D Q36363253-9245C0F5-8604-490A-8287-A69E16029C85 Q36403500-04E6B823-5EC5-4B76-B0B8-0E8344291905 Q36443292-F8C743D6-DC4D-416B-831E-8E4EA35F58E5 Q36522002-01344399-C68B-40FA-BC29-8ED59C5BDF38 Q36835666-86369B66-463C-43D9-82D7-995292A409F5 Q37310749-33BBC562-2B27-43AF-A094-2CFCA3C6DDC5 Q37433779-2745CD20-FFE8-4B73-9AAC-24CC8FA512B6 Q37709086-C613C7C6-B49B-49DA-9416-5C32080B8187 Q38524949-C4348DD9-813D-46FE-8CDE-11286B26A78E Q38591847-C5880586-08F3-4869-8A42-965A46E487F6 Q38603013-DB257219-6E9C-44F6-A72F-12FB50D5B57C Q38617605-753E04EC-1339-4F2A-8C1D-BCCEEC3A3BB7 Q38618187-922CD2FB-5AD3-4431-A381-9620A1AF1AE3 Q38651811-843C3960-EBD3-4547-AB00-1FF0FDA56A90 Q38656763-238994FE-25D4-4EF6-9FE4-B48A9542A703 Q38788622-AD86C1D9-7549-459A-911C-F1C836D22ECA Q38789397-C915C3B7-6A6B-415B-9680-4BBFE61E882D Q38793629-20530785-80F1-4764-AD38-448546ABD87B Q38816533-0D4F5330-120A-41EB-9545-098845E85DEB Q38889573-3FF9F2F3-12C1-40E9-98E9-954E1654C0EC Q38904658-92FBC687-1CD4-42FA-A7E6-7961930573A3 Q38920677-C75F5768-1988-4896-9E8A-0B68646DD6F3 Q38956790-84DD51E1-431F-4F0C-A56D-A9617E42DB1E

P2860

Lipid nanoparticle siRNA treatment of Ebola-virus-Makona-infected nonhuman primates.

http://www.wikidata.org/entity/Q34473079

description

2015 nî lūn-bûn

@nan

2015 թուականի Ապրիլին հրատարակուած գիտական յօդուած

@hyw

2015 թվականի ապրիլին հրատարակված գիտական հոդված

@hy

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

name

Lipid nanoparticle siRNA treatment of Ebola-virus-Makona-infected nonhuman primates.

@ast

Lipid nanoparticle siRNA treatment of Ebola-virus-Makona-infected nonhuman primates.

@en

Lipid nanoparticle siRNA treatment of Ebola-virus-Makona-infected nonhuman primates.

@nl

type

label

Lipid nanoparticle siRNA treatment of Ebola-virus-Makona-infected nonhuman primates.

@ast

Lipid nanoparticle siRNA treatment of Ebola-virus-Makona-infected nonhuman primates.

@en

Lipid nanoparticle siRNA treatment of Ebola-virus-Makona-infected nonhuman primates.

@nl

prefLabel

Lipid nanoparticle siRNA treatment of Ebola-virus-Makona-infected nonhuman primates.

@ast

Lipid nanoparticle siRNA treatment of Ebola-virus-Makona-infected nonhuman primates.

@en

Lipid nanoparticle siRNA treatment of Ebola-virus-Makona-infected nonhuman primates.

@nl

P1433

Q34473079-FBFD965D-F408-4284-9A76-862CF180D258

P1476

Q34473079-1FFB074A-730E-47A2-AC96-E84166B0B01E

P2093

Q34473079-2B55A9F8-A141-4514-870A-54ACEC29EEC4

Q34473079-34938BFC-BF22-4EC9-A4B5-B18F3C5A13BD

Q34473079-4D7D3675-9222-48FE-B602-C706655912C9

Q34473079-60F070C7-5371-4CF7-983C-040399EACFD4

Q34473079-766988FF-96A2-4E10-A055-2CA1E2D2EB2A

Q34473079-9431AA2B-9CC7-47FD-94D2-251F00567E5E

Q34473079-BC15F368-AEA5-4BF1-8444-7C18E8A6A8F0

Q34473079-CFA5A076-75E1-4EBE-BB8B-30D78CF3D6C0

Q34473079-D0FB05FC-8AB5-45DD-98AB-DA3AC47B9106

Q34473079-D3CD6A7D-B557-4C06-A692-492A2A14A492

P2860

Q34473079-0F17C9A3-C5F7-42B6-9D71-5E3FC8BB748D

Q34473079-0FBB9311-7AAB-4271-ACE5-EDF133163D09

Q34473079-2EF6F4FD-A587-4212-91C2-E9CE2539B32E

Q34473079-45148EDA-1E81-43BA-BF23-B5448FBD29DA

Q34473079-4FC41E40-1380-4DE6-8155-FEC91438E28E

Q34473079-53B69739-69A0-4A18-B9E6-FD0AAFB4B44D

Q34473079-6E38FDF3-B44A-4C0B-ABA6-91E7D606BA27

Q34473079-7D259741-39DD-416F-8CE0-A9B1F6F2D4F1

Q34473079-8D04908B-1676-4AAB-8683-3D5DB4BB7FF2

Q34473079-9442AC84-B262-4719-B168-2DA4A4C71815

P2888

Q34473079-DD7DC344-1C50-4252-B9DD-1FB7CDB64593

P304

Q34473079-62668879-4A2D-4540-BE33-D816C32F6A07

P31

Q34473079-DE127E53-2DE6-4DBF-BC68-7C4A89CC877B

P356

Q34473079-4F35CC03-A748-49C1-B395-3DC2F31295B6

P407

Q34473079-527DB119-66D0-4996-A827-B2D37F5E64C3

P433

Q34473079-C6353BC6-3EEF-44C1-8EB2-3269C1BBCE2B

P478

Q34473079-C94710C0-8200-467E-8630-CDE364FA4A9A

P50

Q34473079-559F7AC7-6879-462C-AB7B-99C4ED61BBF3

P577

Q34473079-2380F184-9B0A-4813-83E3-4AEB64028027

P5875

Q34473079-77FFE9AF-5CBB-43CF-BD58-9DA93EC6CC93

P6179

Q34473079-C045987E-3F09-40CD-9E0E-7D1BD26EAA11

P698

Q34473079-37F5D101-AB4D-47BE-AA65-D2C46AA2570E

P921

Q34473079-89F8BB39-2E73-484E-B381-E87A6C3903F1

Q34473079-B25666E1-DC34-4F50-89C0-66B201783885

P932

Q34473079-1DD176FD-0130-4A79-9FFD-DFCFC759B5DE

P356

P1433

P1476

Lipid nanoparticle siRNA treatment of Ebola-virus-Makona-infected nonhuman primates.

@en

P2093

Amy C H Lee

http://www.w3.org/2001/XMLSchema#string

Chad E Mire

http://www.w3.org/2001/XMLSchema#string

Daniel J Deer

http://www.w3.org/2001/XMLSchema#string

Emily P Thi

http://www.w3.org/2001/XMLSchema#string

Ian MacLachlan

http://www.w3.org/2001/XMLSchema#string

Joan B Geisbert

http://www.w3.org/2001/XMLSchema#string

Joy Z Zhou

http://www.w3.org/2001/XMLSchema#string

Karla A Fenton

http://www.w3.org/2001/XMLSchema#string

Krystle N Agans

http://www.w3.org/2001/XMLSchema#string

Nicholas M Snead

http://www.w3.org/2001/XMLSchema#string

P2860

Genomic surveillance elucidates Ebola virus origin and transmission during the 2014 outbreak

A systematic analysis of the silencing effects of an active siRNA at all single-nucleotide mismatched target sites

Emergence of Zaire Ebola Virus Disease in Guinea

Designing siRNA that distinguish between genes that differ by a single nucleotide

Treatment of Ebola virus infection with a recombinant inhibitor of factor VIIa/tissue factor: a study in rhesus monkeys.

Postexposure protection of non-human primates against a lethal Ebola virus challenge with RNA interference: a proof-of-concept study.

Reversion of advanced Ebola virus disease in nonhuman primates with ZMapp

Ebola virus genome plasticity as a marker of its passaging history: a comparison of in vitro passaging to non-human primate infection.

Formulated minimal-length synthetic small hairpin RNAs are potent inhibitors of hepatitis C virus in mice with humanized livers.

Evaluation of the potential impact of Ebola virus genomic drift on the efficacy of sequence-based candidate therapeutics.

P2888

P304

362-365

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/NATURE14442

http://www.w3.org/2001/XMLSchema#string

P407

P433

7552

http://www.w3.org/2001/XMLSchema#string

P478

521

http://www.w3.org/2001/XMLSchema#string

P50

Thomas W Geisbert

P577

2015-04-22T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

275361788

http://www.w3.org/2001/XMLSchema#string

P6179

1051984842

http://www.w3.org/2001/XMLSchema#string

P698

25901685

http://www.w3.org/2001/XMLSchema#string

P921

P932

4467030

http://www.w3.org/2001/XMLSchema#string